NASDAQ:NEOSNeos Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.70 +0.01 (+1.46 %) (As of 07/1/2020 04:00 PM ET) Add Compare Share Today's Range$0.69Now: $0.70▼$0.7150-Day Range$0.69MA: $0.75▼$0.9052-Week Range$0.60Now: $0.70▼$2.15Volume64,630 shsAverage Volume195,944 shsMarket Capitalization$34.67 millionP/E RatioN/ADividend YieldN/ABeta1.28 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingNeos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Neos Therapeutics has a potential upside of 330.4% from its current price of $0.70.Amount of Analyst CoverageNeos Therapeutics has received no research coverage in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesNeos Therapeutics has received 500 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeos Therapeutics has received 300 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeos Therapeutics has received 62.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote “Outperform” if you believe NEOS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeos Therapeutics does not currently pay a dividend.Dividend GrowthNeos Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Neos Therapeutics is held by insiders.Percentage Held by Institutions39.19% of the stock of Neos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neos Therapeutics are expected to grow in the coming year, from ($0.23) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neos Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neos Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEOS Previous Symbol CUSIPN/A CIK1467652 Webwww.neostx.com Phone972-408-1300Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$64.65 million Price / Sales0.54 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-5.81Profitability EPS (Most Recent Fiscal Year)($0.34) Net Income$-16,900,000.00 Net Margins-26.52% Return on EquityN/A Return on Assets-18.96%Miscellaneous Employees215 Outstanding Shares49,740,000Market Cap$34.67 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:NEOS Rates by TradingView Receive NEOS News and Ratings via Email Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter. Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions How has Neos Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NEOS stock has decreased by 49.5% and is now trading at $0.6970. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Neos Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Neos Therapeutics. When is Neos Therapeutics' next earnings date? Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Neos Therapeutics. How were Neos Therapeutics' earnings last quarter? Neos Therapeutics Inc (NASDAQ:NEOS) posted its earnings results on Monday, May, 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.06. The company had revenue of $14.49 million for the quarter. View Neos Therapeutics' earnings history. What price target have analysts set for NEOS? 1 brokerages have issued 12 month target prices for Neos Therapeutics' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Neos Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 330.4% from the stock's current price. View analysts' price targets for Neos Therapeutics. Has Neos Therapeutics been receiving favorable news coverage? Media headlines about NEOS stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neos Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Neos Therapeutics. Are investors shorting Neos Therapeutics? Neos Therapeutics saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 1,180,000 shares, a decline of 49.6% from the May 31st total of 2,340,000 shares. Based on an average daily volume of 217,200 shares, the days-to-cover ratio is currently 5.4 days. Currently, 2.4% of the shares of the stock are short sold. View Neos Therapeutics' Current Options Chain. Who are some of Neos Therapeutics' key competitors? Some companies that are related to Neos Therapeutics include Mustang Bio (MBIO), InflaRx (LUMO), Rockwell Medical (RMTI), Harrow Health (HROW), PhaseBio Pharmaceuticals (PHAS), Iterum Therapeutics (NRBO), Savara (SVRA), ESSA Pharma (EPIX), Conatus Pharmaceuticals (CNAT), Sierra Oncology (SRRA), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), Genprex (GNPX), Inflarx (IFRX) and Celsion (CLSN). View all competitors. What other stocks do shareholders of Neos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Verastem (VSTM), Exelixis (EXEL), Fibrocell Science (FCSC), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), SCYNEXIS (SCYX), Trevena (TRVN), Agile Therapeutics (AGRX) and BioDelivery Sciences International (BDSI). Who are Neos Therapeutics' key executives? Neos Therapeutics' management team includes the following people: Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 61)Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 51)Mr. John P. Limongelli, Sr. VP & Gen. Counsel (Age 49)Mr. Darren Heath, VP of SalesMr. Russ McMahen, Sr. VP of R&D When did Neos Therapeutics IPO? (NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. What is Neos Therapeutics' stock symbol? Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS." How do I buy shares of Neos Therapeutics? Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neos Therapeutics' stock price today? One share of NEOS stock can currently be purchased for approximately $0.70. How big of a company is Neos Therapeutics? Neos Therapeutics has a market capitalization of $34.67 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe. What is Neos Therapeutics' official website? The official website for Neos Therapeutics is www.neostx.com. How can I contact Neos Therapeutics? Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected] This page was last updated on 7/2/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
